Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab and Donafenib in Advanced Solid Tumors
NCT04472858Phase 1Unknown
- Sponsor
- Zelgen
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sugemalimab and donafenib in solid tumor (advanced stage), cholangiocarcinoma (CCA), head and neck squamous cell carcinoma (HNSCC) and 1 more (4 arms), sponsored by Zelgen. Primary endpoints: Number of participants with adverse events, Dose Limiting Toxicity and 3 more. Status: unknown.
02
Drugs
sugemalimabdonafenib
03
Conditions
solid tumor (advanced stage)cholangiocarcinoma (CCA)head and neck squamous cell carcinoma (HNSCC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04472858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472858.